#WorldLungCancerDay В Україні рак легені залишається однією з головних причин смертності від онкологічних хвороб серед чоловіків. Тривалий час страх і стереотипи про відсутність доступної терапії зупиняли людей від своєчасного звернення до лікаря. У Всесвітній день боротьби з раком легені ми прагнемо нагадати: турбота про здоров'я починається з уваги до себе. Виявлення захворювання на ранніх стадіях відкриває значно більше можливостей для ефективної терапії та збереження якості життя. У Roche ми переконані: справжні зміни відбуваються тоді, коли наукові досягнення, державна політика та голос пацієнтів об'єднуються. Спільно з органами охорони здоров'я та пацієнтською спільнотою ми працюємо над розширенням доступу до необхідної допомоги. 🫁Розширення доступу: Завдяки Договорам керованого доступу пацієнти з раком легені на ранніх стадіях, які відповідають визначеним критеріям, отримують безоплатне лікування за кошт держави по всій Україні. 🤝Інвестиції та партнерство: Покрокова реалізація проєкту з локалізації виробництва онкопрепаратів в Україні — це наш внесок у розвиток медичної системи та запорука стабільного доступу пацієнтів до терапії. 📢Голос пацієнта: Ми постійно співпрацюємо з пацієнтськими організаціями, щоб покращувати кожен етап маршруту пацієнта. Якщо ви або ваші близькі перебуваєте в групі ризику — не відкладайте, проконсультуйтеся зі своїм лікарем вже сьогодні. #WorldLungCancerDay #HealthcarePartnerships #RocheUkraine #OncologyCare
Info
Roche ist ein globales Unternehmen mit Vorreiterrolle in der Erforschung und Entwicklung von Medikamenten und Diagnostika und ist darauf fokussiert, Menschen durch wissenschaftlichen Fortschritt ein besseres, längeres Leben zu ermöglichen. Dank der Kombination von Pharma und Diagnostika unter einem Dach ist Roche führend in der personalisierten Medizin - einer Strategie mit dem Ziel, jeder Patientin und jedem Patienten die bestmögliche Behandlung zukommen zu lassen. Roche ist das grösste Biotech-Unternehmen weltweit mit differenzierten Medikamenten für die Onkologie, Immunologie, Infektionskrankheiten, Augenheilkunde und Erkrankungen des Zentralnervensystems. Roche ist auch der bedeutendste Anbieter von In-vitro-Diagnostika und gewebebasierten Krebstests und ein Pionier im Diabetesmanagement. Seit der Gründung im Jahr 1896 erforscht Roche bessere Wege, um Krankheiten zu verhindern, zu erkennen und zu behandeln und leistet einen nachhaltigen Beitrag zur gesellschaftlichen Entwicklung. Zum Ziel des Unternehmens gehört es durch Kooperationen mit allen relevanten Partnern den Zugang von Patienten zu medizinischen Innovationen zu verbessern. Auf der Liste der unentbehrlichen Arzneimittel der Weltgesundheitsorganisation stehen heute 30 von Roche entwickelte Medikamente, darunter lebensrettende Antibiotika, Malariamittel und Krebsmedikamente. Ausgezeichnet wurde Roche zudem bereits das neunte Jahr in Folge als das nachhaltigste Unternehmen innerhalb der Pharma-, Biotechnologie- und Life-Sciences-Branche im Dow Jones Sustainability Index. Die Roche-Gruppe mit Hauptsitz in Basel, Schweiz ist in über 100 Ländern tätig und beschäftigte 2017 weltweit rund 94 000 Mitarbeiterinnen und Mitarbeiter. Im Jahr 2017 investierte Roche CHF 10,4 Milliarden in Forschung und Entwicklung und erzielte einen Umsatz von CHF 53,3 Milliarden. Genentech in den USA gehört vollständig zur Roche-Gruppe. Roche ist Mehrheitsaktionär von Chugai Pharmaceutical, Japan. Weitere Informationen finden Sie unter www.roche.com/careers #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalizedHealthcare #GreatPlaceToWork #Innovation
- Website
-
http://www.roche.com/
Externer Link zu Roche
- Branche
- Biotechnologieforschung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Switzerland 🇨🇭
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- biotechnology, innovation, personalized healthcare, great place to work, diagnostics, pharmaceuticals, research, healthcare, personalised healthcare, diabetes care, genomics, healthcare technology, big data und Science
Orte
Beschäftigte von Roche
Updates
-
Our new sequencing by expansion (SBX) technology relies on a smart nanopore sensor module that translates individual molecules into precise digital data. By utilizing 8 million tiny wells with advanced membrane technology, the system achieves remarkable speed and flexibility in DNA sequencing. See the technology in action: https://lnkd.in/dnZC7VJz (Roche's sequencing technology is currently for research use only.) #NextGenSequencing #Genomics #RocheSBX #BiotechInnovation
-
-
Developing tailored treatments for age-related macular degeneration (AMD) and diabetic retinopathy requires moving past static clinical observations to map real-time disease progression. At Roche pRED, Clinical Research Fellow Rachael Harlow MB BChir, MChD and her colleagues are leveraging our data infrastructure to address this challenge. By analysing massive datasets, including fluid samples collected directly during patient injections, and integrating artificial intelligence, they are working to identify specific retinal features, investigate predictive biomarkers, and map disease progression with unprecedented accuracy. This data-driven framework allows us to accelerate the discovery of targeted therapeutic options at every stage of the patient journey. In this episode of #InsideRocheRnD, we take a look at how our translational ophthalmology teams are transforming patient data into predictive clinical insights. #Ophthalmology #pRED #TranslationalMedicine #ScienceLife
-
We are no longer just hoping for breakthroughs in Alzheimer’s disease, we are seeing them become a reality. From advanced diagnostics that could save precious time, to new ways of crossing the blood brain barrier and delivering medicines directly to the brain, the landscape is shifting. #Alzheimers #Neuroscience #BrainHealth
-
What if sustainability became the starting point for your next big idea? 🌍💡 Real challenges, real teams, real responsibility. We're thrilled to welcome more than 60 interns from over 20 countries to our Global Internship Programme in Innovation & Sustainability (#IP2TIS)! Over the coming months, they'll work on real projects across Science & Innovation, Digital, Technology & AI, Society and Sustainability - transforming ideas into solutions that matter. Because meaningful impact isn't defined by years of experience. It's created when you're trusted to contribute, supported to grow, and empowered to make a difference. To our new #IP2TIS interns: We can't wait to see the future you'll help shape 🌱 Curious? See what #IP2TIS is all about. https://lnkd.in/dqVQZF3R #Roche #IP2TIS #RocheCareers #Innovation #Sustainability #TakeAction
-
Every milestone reflects our shared commitment to improving patients' lives. By advancing science and innovation, we continue doing now what patients need next. Thank you to our teams around the world whose dedication makes this possible. Read our CEO Thomas Schinecker's message below to learn more.
As we report our half-year results today, our strong momentum continued, driven by a 6% sales increase at constant exchange rates and significant positive pipeline development. What matters most is the progress we make for patients. We shared positive phase III data for a potential best-in-class therapy in advanced lung cancer. In addition, our regulatory progress accelerated with five US FDA Priority Reviews — including in early-stage breast cancer, thyroid eye disease, colon cancer and autoimmune kidney disease. In Diagnostics, we reached major milestones with the launch of our new sequencing solution, alongside European CE marks for key diagnostic tests in Alzheimer’s pathology and latent tuberculosis screening. With several exciting launches on the horizon and strong momentum across our entire business, together, we continue to push the boundaries of innovation to prevent, stop and cure diseases, making a meaningful difference in the lives of patients around the world. A big thank you to our employees, partners and customers!
-
Roche continues strong momentum with 6% sales growth (CER) in the first half of 2026 – full-year outlook confirmed. For more details on our performance, click here ➡️ https://spkl.io/60497JsLB
-
People living with haemophilia A deserve the freedom to participate fully in daily life without constant worry around bleeds and treatment burden. As their expectations of what holistic care looks like evolve, so too must the definition of progress in haemophilia A. Explore what meaningful care looks like today in the latest article by John Pasi MBE, Global Head of Haematology and Rare Blood Diseases at Roche 👉 https://spkl.io/60437J93P #HaemophiliaA #BleedingDisorders #PatientCare
Meaningful Care in Haemophilia
-
We join the scientific community worldwide in commemorating the remarkable life and contributions of Susumu Tonegawa, a molecular biologist whose pioneering research was fundamental to our comprehension of the human immune system. Dr. Tonegawa’s tenure at our Basel Institute for Immunology, 1972 to 1981, proved transformative. He took on a fundamental biological puzzle: how our bodies manage to produce a vast array of unique antibodies from a limited genetic template. By revealing the mechanism of gene recombination, he provided the key to understanding how our immune system recognises and defends against an endless variety of pathogens. This breakthrough on antibody gene segments, recognised with the 1987 Nobel Prize in Medicine, advanced basic biology and paved the way for modern immunological therapies, including the development of humanised antibodies that have fundamentally influenced the landscape of patient care. At Roche, we feel a meaningful connection to Dr. Tonegawa’s legacy and are proud to have been part of his scientific journey. We are inspired by his passion and drive to push the frontiers of science. His spirit of inquiry drives our own mission and commitment to trailblaze new scientific research. We honour his memory by carrying forward his passion for discovery, dedicated to turning complex biological insights into meaningful breakthroughs for patients worldwide.
-
-
Roche’s nanopore-based sensor module is the electronic heart of our sequencing by expansion (SBX) innovation. The module contains 8 million microscopic wells, each one spanned by a thin membrane with a single nanopore through which a single molecule can pass. SBX delivers clear, highly accurate DNA sequencing results with speed and efficiency. Learn more: https://lnkd.in/dH9WdQfr (Roche's sequencing technology is currently for research use only.) #NextGenSequencing #Genomics #RocheSBX #BiotechRND